Karyopharm EVP logs tax-related 3,526-share sale

Karyopharm Therapeutics Inc. executive Mano Michael, EVP, CLO & Secretary, reported an open-market sale of 3,526 shares of common stock at an average price of $9.4095 per share.

Accepted by SEC EDGAR 03/03/2026 - 04:28 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Karyopharm Therapeutics Inc. executive Mano Michael, EVP, CLO & Secretary, reported an open-market sale of 3,526 shares of common stock at an average price of $9.4095 per share. According to the disclosure, this broker-assisted sale was made under a durable automatic sale instruction plan and was used solely to cover withholding taxes triggered by the vesting of restricted stock units, rather than a discretionary trade. After this tax-related transaction, Michael held 93,964 shares of Karyopharm common stock directly.

Insider Trade Summary

Net Seller: 3,526 shares

Net Sell 1 txn

Insider Mano Michael

Role EVP, CLO&Secretary

Sold 3,526 shs ($33K)

Share of Position Sold 3.6%

Type	Security	Shares	Price	Value
Sale	Common Stock	3,526	$9.4095	$33K

Holdings After Transaction: Common Stock — 93,964 shares (Direct)

Holdings Before and After: Common Stock, 97,490 to 93,964 shares (Direct)

Other Insiders: 6 other insiders reported open-market sales of this stock in the 30 days up to this filing.

Footnotes (1)

1. F1. This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 16, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Karyopharm (KPTI) executive Mano Michael report on this Form 4?

Karyopharm executive Mano Michael reported selling 3,526 shares of common stock. The shares were sold in an open-market, broker-assisted transaction to cover tax withholding obligations from restricted stock unit vesting, not as a discretionary portfolio trade.

How many KPTI shares did Mano Michael sell and at what price?

Mano Michael sold 3,526 Karyopharm shares at an average price of $9.4095 per share. The transaction was disclosed as an open-market sale conducted by a broker to satisfy withholding tax liabilities tied to vesting restricted stock units.

Why were Karyopharm (KPTI) shares sold by Mano Michael in this filing?

The shares were sold to satisfy withholding tax liability from the vesting of restricted stock units. The filing explains the transaction followed a durable automatic sale instruction plan and was not a discretionary trade initiated for investment reasons by the executive.

Does Mano Michael still hold KPTI shares after this reported sale?

Yes. After the sale of 3,526 Karyopharm shares, Mano Michael directly held 93,964 common shares. This remaining ownership reflects his continuing equity stake as EVP, Chief Legal Officer and Secretary following the tax-related share sale reported in the Form 4.

Was the KPTI insider sale by Mano Michael a discretionary transaction?

No. The filing states the transaction was executed under a durable automatic sale instruction plan. It further clarifies the broker-assisted sale was solely to cover RSU-related tax withholding and therefore does not represent a discretionary trade by the reporting person.

What role does Mano Michael hold at Karyopharm Therapeutics (KPTI)?

Mano Michael is listed as an officer of Karyopharm Therapeutics, serving as Executive Vice President, Chief Legal Officer and Secretary. His Form 4 filing reflects equity activity connected to this leadership position, including tax-related sales following restricted stock unit vesting events.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mano Michael

(Last) (First) (Middle)

C/O KARYOPHARM THERAPEUTICS INC.

85 WELLS AVENUE

(Street)

NEWTON MA 02459

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Karyopharm Therapeutics Inc. [ KPTI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, CLO&Secretary

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/02/2026		S(1)		3,526	D	$9.4095	93,964	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 16, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.

	/s/ Nancy Smith as Attorney-in-Fact for Michael Mano	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.